medigraphic.com
ISSN 1561-2937 (Print)

2020, Number 3

Next >>

Rev Cubana Cardiol Cir Cardiovasc 2020; 26 (3)

Effectiveness of percutaneous coronary intervention with paclitaxel eluting stent versus bare metal stent.

Aroche AR, Rodríguez NAY, García ORA, Hernández NM, Obregón SAG, Aldama PL

Language: Spanish
References: 38
Page: 1-11
PDF size: 409.02 Kb.


ABSTRACT

Introduction: Heart disease is the leading cause of death in Cuba and the world. Percutaneous coronary intervention with drug eluting stents is a fundamental pillar of its treatment. Objective: To evaluate the effectiveness of percutaneous coronary intervention with paclitaxel eluting stents compared to bare metal stents in patients treated at CIMEQ. Method: Analytical prospective longitudinal study in 318 randomized patients (1:1) to a group treated with paclitaxel eluting stent and an identical stainless steel one, followed by three years to evaluate survival free of major adverse cardiac events (death / non-fatal myocardial infarction and need for new revascularization), restenosis and stent thrombosis. Frequency distribution, test χ2 , Fisher's test and T-Test of difference between means, Kaplan-Meier curve and Mantel-Cox test were used, with statistical significance (α <0.05). This research was in line with the Helsinki declaration and was approved by the ethic and scientific council. Results: Restenosis in the group with a paclitaxel eluting stent was 15.7% compared to 24.5% in the bare metal stent; p = 0.05. The survival free of combined major adverse cardiac events was higher in the same group 78.2% vs. 68.4%, p = 0.045. The incidence of thrombosis was low in both groups (paclitaxel eluting stents: 3.7% and 5.0% in bare metal stents; p = 0.58). Conclusions: Treatment with paclitaxel eluting stent provides superior survival free of combined major adverse cardiac events, due to the decrease in restenosis and the need for new target lesion revascularization. However, mortality, stent thrombosis, and the incidence of myocardial infarction are similar with both stents.


REFERENCES

  1. Cuba. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. Cardiopatía isquémica. Estadísticas Mundiales. Factográfico salud [Internet]. 2019 Feb [citado 30 abril 2019]; 5(2):[aprox. 11 p.]. Disponible en: http://files.sld.cu/bmn/files/2019/02/factografico-de-salud-febrero-2019.pdf

  2. Tomberli B, Mattesini A, Baldereschi GI, Di Mario C. Breve historia de los stents coronarios. Revista Española de Cardiología [Internet]. mayo de 2018 [citado 11 de junio de 2019];71(5):312-9. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0300893217307443

  3. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation [Internet]. 20 de marzo de 2007 [citado 11 de junio de 2019];115(11):1440-55. Disponible en: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.106.666800 1455.

  4. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. BASKET-LATE Investigators. Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. Journal of the American College of Cardiology [Internet]. diciembre de 2006 [citado 10 de junio de 2019];48(12):2584-91. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S073510970602523X

  5. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L.SCAAR Study Group.Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. N Engl J Med [Internet]. 8 de marzo de 2007 [citado 11 de junio de 2019];356(10):1009-19. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa067722

  6. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. The Lancet [Internet]. febrero de 2007 [citado 11 de junio de 2019];369(9562):667-78. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0140673607603146

  7. Gargiulo G, Valgimigli M, Capodanno D, Bittl J. State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives. EuroIntervention [Internet]. agosto de 2017 [citado 8 de junio de 2019]; 13(6):717-33. Disponible en: http://www.pcronline.com/eurointervention/120th_issue/108

  8. Galløe AM, Kelbæk H, Thuesen L, Hansen HS, Ravkilde J, Hansen PR, et al. 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. Journal of the American College of Cardiology [Internet]. febrero de 2017 [citado 8 de junio de 2019];69(6):616-24.Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0735109716373363

  9. Piegas LS, Haddad N. Intervenção coronariana percutânea no Brasil: resultados do Sistema Único de Saúde. Arq Bras Cardiol [Internet]. abril de 2011 [citado 8 de mayo de 2019];96(4):317-24. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011000400010&lng=pt&nrm=iso&tlng=en

  10. Lee JH, Kim ED, Jun EJ, Yoo HS, Lee JW. Analysis of trends and prospects regarding stents for human blood vessels. Biomater Res [Internet]. diciembre de 2018 [citado 4 de junio de 2019]; 22(1):8. Disponible en: https://biomaterialsres.biomedcentral.com/articles/10.1186/s40824-018-0114-1

  11. Sousa GMRA, Botelho G, Reinhold U,Maldonado GA, Sousa JE. Registro SOLACI: un perfil de desempeño de la cardiología intervencionista en América Latina. En: Sousa GMRA, Abizaid A, Martinez RM, Berrocal D, Sousa JE. Intervenciones cardiovasculares SOLACI. 2da ed. Editorial Distribuna. Bogotá, 2009.p.18-25.

  12. Cuba. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario Estadístico de Salud 2018 [Internet]. La Habana: MINSAP; 2019 [citado 21 mayo 2019]. Disponible en: Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/

  13. García E, Serra A, Zueco JJ, Larman M, Rumoroso JR, Moreu J, et al. Long-Term Clinical Performance of Paclitaxel-Eluting Stents Coated Witha Bioactive Polymer (P-5) Containing a Triflusal Derivative: Results of the REWAC Registry. J invasive cardiol 2013;25(8):391-396. Disponible en: https://www.researchgate.net/publication/255178558

  14. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al. Clinical End Points in Coronary Stent Trials. Circulation [Internet]. 1 de mayo de 2007 [citado 7 de junio de 2020];115(17):2344-51. Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.106.685313

  15. Cutlip DE, Nakazawa G, Krucoff MW, Vorpahl M, Mehran R, Finn AV, et al. Autopsy Validation Study of the Academic Research Consortium Stent Thrombosis Definition. J Am Coll Cardiol Intv [Internet]. 1 de mayo de 2011 [citado 7 de junio de 2020];4(5):554-9. Disponible en: https://interventions.onlinejacc.org/content/4/5/554

  16. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphology and clinical determinants of proceduraloutcome with angioplasty for multivessel coronary disease: Implications forpatient selection. Circulation 1990;82:1193-202.

  17. 17.Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD, et al. Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. Journal of the American College of Cardiology [Internet]. marzo de 2007 [citado 9 de junio de 2019];49(10):1043-51. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0735109707002161

  18. Bonet M, Varona P, La Rosa MC, García RG, Suárez R, Ar-cia N, et al. III Encuesta nacional de factores de riesgo y actividades preventivas de enfermedades no trasmisibles. Cuba 2010-2011 [Internet]. La Habana;Ciencias Médicas; 2014 [citado 8 Mayo 2019]. Disponible en: http://especialidades.sld.cu/higienepidemiologia/2014/08/23/iii-encuestanacional-de-factores-de-riesgo-y-actividades-preventivas-de-enfermedadesno-trasmisibles-cuba-2010-2011/

  19. Estrada J, Pimentel G, Carreón G, Navarro L, López J, González B, et al. Stent liberador de paclitaxel (active): registro de un solo centro. Rev Mex Cardiol [Internet]. Diciembre 2012; 23 (4): 178-179. [citado 8 Mayo 2019]. Disponible en: http://www.scielo.org.mx/pdf/rmc/v23n4/v23n4a1.pdf

  20. Leyva QAY, León GM, Valdés RMA, Ponte GG, Mendoza OJL, Rodríguez BS. Factores asociados a la recurrencia de la re-estenosis intrastent coronario convencional. Rev Cubana Cardiol Cir Cardiovasc [Internet]. 2015 [citado 2019 Jun 10];21(1):[aprox. 6 p.]. Disponible en: http://www.revCardiología.sld.cu/index.php/revCardiología/article/view/564

  21. López PJE, Filgueiras FE, Aroche AR, Llerena RL, López FL, Obregón SAG,et al. Seguimiento a cuatro años de pacientes con stent Firebird liberador de sirolimus en Cuba. Rev Fed Arg Cardiol[revista en Internet]. 2010[citado 2019 mayo 19]; 39 (2): 105-109:[aprox. 4 p.] Disponible en: http://www.fac.org.ar/1/revista/10v39n2/art_orig/arorig02/lopez_perez.php

  22. Aldama PLI, Hernández NM, Cuba RAL, Naranjo DA, Aroche AR, Martínez JO. Intervención coronaria percutánea en la enfermedad arterial del tronco coronario izquierdo.. Rev Cubana Cardiol Cir Cardiovasc [Internet]. 2019 [citado 2019 Jun 10];25(1):[aprox. 10 p.]. Disponible en: http://www.revCardiología.sld.cu/index.php/revCardiología/article/view/840

  23. Pacheco GG, Obregón SAG, Aroche AR, Conde CH, Hernández NM, Gandarilla SJC. Factores clínicos y del procedimiento relacionados con la trombosis de stent. CorSalud 2012[Internet];4(2):97-102. [citado 11 de junio de 2019]. Disponible en: http://www.corsalud.sld.cu/sumario/2012/v4n2a12/trombosis.htm

  24. Hernández NM, Aroche AR, Aldama PL, Obregón SÁG, Gil TIJ, Leal HE. Importancia clínica del sangrado en pacientes con intervencionismo coronario percutáneo por vía radial en el CIMEQ. CorSalud [Internet]. 2015[citado 2019 Jun 10];7(3):606. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/55

  25. Ahmad M, Schwalm J-DR, Velianou JL, Pericak D, Natarajan MK. Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice. Canadian Journal of Cardiology [Internet]. octubre de 2008 [citado 10 de junio de 2019];24(10):771-5. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0828282X08706822

  26. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions. Circulation [Internet]. 7 de enero de 2003 [citado 16 de junio de 2019];107(1):38-42. Disponible en: https://www.ahajournals.org/doi/10.1161/01.CIR.0000047700.58683.A1

  27. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, et al. Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions. Circulation [Internet]. 13 de octubre de 2009 [citado 16 de junio de 2019];120(15):1498-504. Disponible en: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.849877

  28. Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo A, et al. TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention [Internet]. marzo de 2009[citado 16 de junio de 2019];4(5):572-7. Disponible en: https://eurointervention.pcronline.com/article/taxus-vi-final-5-year-results-a-multicentre-randomised-trial-comparing-polymer-based-moderate-release-paclitaxel-eluting-stent-with-a-bare-metal-stent-for-treatment-of-long-complex-coronary-artery-lesions

  29. Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo A, et al. TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention [Internet]. marzo de 2009[citado 16 de junio de 2019];4(5):572-7. Disponible en: https://eurointervention.pcronline.com/article/taxus-vi-final-5-year-results-a-multicentre-randomised-trial-comparing-polymer-based-moderate-release-paclitaxel-eluting-stent-with-a-bare-metal-stent-for-treatment-of-long-complex-coronary-artery-lesions

  30. Ellis SG, Stone GW, Cox DA, Hermiller J, O’Shaughnessy C, Mann T, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY : Cardiovascular Interventions [Internet]. diciembre de 2009 [citado 16 de junio de 2019];2(12):1248-59. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1936879809006712

  31. Stone GW, Ellis SG, O’Shaughnessy CD, Martin SL, Satler L, McGarry T, et al. Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The TAXUS V ISR Randomized Trial. JAMA [Internet]. 15 de marzo de 2006 [citado 16 de junio de 2019];295(11):1253. Disponible en: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.11.1253

  32. Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY : Cardiovascular Interventions [Internet]. junio de 2009 [citado 10 de junio de 2019];2(6):515-23. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1936879809002167

  33. Qian F, Zhong Y, Kheocha-on T, Hannan E. Comparison of long-term outcomes of bare-metal and paclitaxel-eluting stents in New York: Bare-metal vs paclitaxel-eluting stents. J Eval Clin Pract [Internet]. diciembre de 2016 [citado 10 de junio de 2019];22(6):975-81. Disponible en: http://doi.wiley.com/10.1111/jep.12575

  34. Zhu J, Zhang Q, Chen L, Zhang C, Zhou X, Yuan Y, et al. Three-Year Clinical Outcomes of a Polymer-Free Paclitaxel-Eluting Microporous Stent in Real-World Practice: Final Results of the Safety and Efficacy Registry of the Yinyi Stent (SERY-I). Acta Cardiol Sin. [Internet]. enero de 2017[citado 10 de junio de 2019];33(1):28-33. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241433/

  35. Unverdorben M, Degenhardt R, Wiemer M, Horstkotte D, Schneider H, Nienaber C, et al. The Paclitaxel-Eluting Coroflex™ Please Stent Pilot Study (PECOPS I): The one-year clinical follow-up. Clin Res Cardiol [Internet]. noviembre de 2007 [citado 10 de junio de 2019];96(11):803-11. Disponible en: http://link.springer.com/10.1007/s00392-007-0560-6

  36. Milojevic M, Head SJ, Parasca CA, Serruys PW, Mohr FW, Morice M-C, et al. Causes of Death Following PCI Versus CABG in Complex CAD. Journal of the American College of Cardiology [Internet]. enero de 2016 [citado 10 de junio de 2019];67(1):42-55. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S073510971507117X

  37. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. European Heart Journal [Internet]. 13 de noviembre de 2006 [citado 10 de junio de 2019];27(23):2784-814. Disponible en: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehl282

  38. Mauri L, Hsieh W, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE. Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents. N Engl J Med [Internet]. 8 de marzo de 2007 [citado 10 de junio de 2019];356(10):1020-9. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa067731




2020     |     www.medigraphic.com